What is the official ID of this bill?
The official print number for this legislation is HR 6977.
Drug Value Assessments: More Transparency in Prices and Patient Benefits
This bill aims to introduce independent drug value assessments, helping citizens better understand drug costs and benefits. Patients and their families will have access to clear information, influencing their health and financial decisions. These assessments will cover both new and existing drugs, with a focus on the most expensive ones.
Key points
Independent Drug Value Assessments: Reports analyzing drug benefits and costs will be publicly available.
Impact on Drug Prices: Assessments will include estimated prices or price ranges commensurate with a drug's actual benefits, potentially influencing price negotiations.
Priority for Expensive Drugs: High-expenditure drugs and breakthrough therapies will be assessed first.
Patient Input: Organizations conducting assessments must consider patient opinions and the drug's impact on their lives.
Prohibition of Controversial Methods: Assessments cannot use quality-adjusted life year (QALY) analysis or discriminate based on age, illness, or disability.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.